2- Inhibition of the coronavirus uncoating
Chloroquine has shown in-vitro effects such as inhibition of uncoating and glycosylation in various viruses, so it is an appropriate case study for COVID-19 treatment according to accomplished clinical trials conducted in China (5). In chloroquine administration, caution must be taken since profound side effects such as retinopathy may proceed. Chloroquine co-administration with lopinavir/ritonavir causes prolonged QT interval, torsades de pointes, and may result in sudden death (30). Pruritus is common. Rare adverse effects include hemolysis in glucose- 6-phosphate dehydrogenase (G6PD)-deficient persons, agranulocytosis, hypotension, and electrocardiographic changes(28).